Spotlight 2022 JP Morgan Conference Illumina Announces Technology Updates and Multiple Collaborations

The 40th JP Morgan Healthcare Conference will be held online from January 10-13, 2022

deSouza first updated Illumina's installed base and user count

Last year, Illumina set new records in all areas, including consumables for the research and clinical markets, NovaSeq shipments for high-throughput markets, NextSeq 1000/2000 shipments for mid-throughput markets, and shipments for low-throughput markets MiniSeq and iSeq 100 shipments in the market

technology Update

deSouza gave a brief introduction to the upcoming new technology

This quarter, Illumina will launch a new bioinformatics platform, the DRAGEN Graph, which supports DNA, RNA and methylation analysis and employs a new Bayesian approach to machine learning that is faster and more affordable and more accurate analysis

After that, deSouza said the company is about to launch Infinity technology to sequence hard-to-reach regions of the genome

Diagnostic partner

Illumina will work to expand its market share in areas such as oncology, reproductive health, and genetic diseases, deSouza said

Oncology testing is a $75 billion market, deSouza mentioned, but currently only has 4% penetration

GRAIL, a subsidiary of Illumina, was spun off from the company in 2016 and acquired by Illumina in 2021

Illumina is leading the $14 billion market for therapy options, deSouza said, highlighting 11 partnerships for TruSight comprehensive oncology assays, including the just-announced partnership with Boehringer Ingelheim, and 34 IVD development partnerships , including a partnership with Agendia announced this week

The collaboration with Boehringer Ingelheim aims to help patients with advanced disease choose treatment and enable precision medicine

The collaboration with Agendia will leverage Illumina's MiSeq™ Dx sequencing platform to develop new assays to enhance the medical care and disease management of breast cancer patients and expand the use of gene panels in solid tumor analysis

Emerging Markets

Illumina's use in infectious disease, drug discovery and proteomics is also growing, deSouza added

Illumina sequencing platforms, bioinformatics solutions DRAGEN ICA, and artificial intelligence-based genome interpretation can also support drug discovery, he said

In the end, deSouza said, the potential size of the proteomics market exceeds $50 billion, and NGS is emerging as the leading readout for proteomics research

Last week, the two companies announced the joint development of a proteomics solution